<DOC>
	<DOCNO>NCT01758146</DOCNO>
	<brief_summary>To see impact obesity efficacy adjuvant endocrine therapy aromatase inhibitor postmenopausal patient early breast cancer term : ) Locoregional recurrence ii ) Distant metastases iii ) Disease-free survival iv ) Overall survival</brief_summary>
	<brief_title>Impact Obesity Efficacy Endocrine Therapy With Aromatase Inhibitors</brief_title>
	<detailed_description>The relationship obesity breast cancer complex one . Obesity risk factor development breast cancer postmenopausal woman link increase risk recurrence decrease survival compare patient normal weight . The hypothesis lead study amount total-body aromatization capacity indicate body mass index ( BMI ) . In postmenopausal woman premenopausal woman ovarian suppression , major source serum estrogens fat tissue , precursor metabolize estrogen enzyme aromatase . Thus , increase BMI lead increase total-body aromatization , consequently , increase oestrogen serum level , impact breast cancer . Taken together , suggest BMI may serve useful surrogate parameter total-body aromatization eventually may practicable tool tailor aromatase inhibitor ( AIs ) therapy individual patient . The study include 360 , postmenopausal patient early breast cancer hormone receptor positive tumour define expression oestrogen receptor ( ER ) and/or progesterone receptor ( PR ) . Patients randomly assign receive tamoxifen 20 mg daily AIs ( letrozole 2.5mg/ anastrozole 1mg/exemestane 25mg ) daily five year . Patients tumour stage IB , IC , II irrespective nodal stage ( &lt; 10 positive node ) include . Weight height take baseline calculation BMI accord WHO criterion . The frequency adverse event use assess safety throughout study . The primary end point disease-free survival ( DFS ) . Secondary end point recurrence-free survival overall survival ( OS ) . The data analyze DFS OS accord BMI subgroup well two treatment arm ( tamoxifen v AIs ) . The frequency adverse event use assess safety throughout study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>postmenopausal patient breast cancer hormone receptor positive tumour define expression oestrogen receptor ( ER ) and/or progesterone receptor ( PR ) . patient tumour stage IB , IC , II irrespective nodal stage ( &lt; 10 positive node ) premenopausal patient , ER/PR negative</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>obesity</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>postmenopausal</keyword>
</DOC>